Month: August 2024

IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days. About CG OncologyCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential...

NAARDEN, The Netherlands and MIAMI, Aug. 30, 2024 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: Morgan Stanley 22nd Annual Global Healthcare Conference in New York City, NY. Company management will host 1×1 meetings on Thursday, September 5, 2024, and Ian Somaiya, Chief Financial Officer, will participate in a fireside chat on Friday, September 6, 2024, at 10:00 a.m. ET; and Cantor Global...

Reference is made to the notice on 29 August 2024 regarding settlement of a term payment on a convertible loan by issue of 9,123,333 shares at NOK 0.60 per share. The share capital has been registered and the shares will be delivered soonest. Following the issue, the company’s share capital is NOK 50,812,483.20 divided into 338,749,888 shares, each with a nominal value of NOK 0.15. For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.comTel: +47 918 00186 About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary...

To Nasdaq Copenhagen Nykredit Realkredit A/S – Extraordinary General Meeting on 30. August 2024 At the Extraordinary General Meeting of Nykredit Realkredit A/S held on Friday 30 August 2024, a resolution passed by the Board of Directors to distribute dividend of DKK 2.200 billion was approved. Copenhagen, 30 August 2024 Nykredit Realkredit A/SBoard of Directors ContactIf you have any questions, please contact Press Relations, tel +45 31 21 06 39. Attachment Extraordinary_General_Meeting_Nykredit Realkredit_A_S_2024-08-30_EN

DALLAS, Aug. 30, 2024 (GLOBE NEWSWIRE) — Berry Corporation (bry) (NASDAQ: BRY) (“Berry” or the “Company”) is reaffirming its strong liquidity position consisting of $94 million of available borrowing capacity under its reserve-based lending (“RBL”) facility and $11 million of cash as of August 23, 2024, as well as its expectation of significant free cash flow generation continuing during the second half of 2024. As of August 23, 2024, the Company’s borrowings outstanding under its RBL facility were $22 million, reflecting a reduction of approximately 57%, or $29 million, since the first quarter of 2024. This reduction included the final payment of $20 million made in July on the 2023 Macpherson transaction. The Company maintains $125 million of available borrowing capacity until the RBL facility matures on August 26, 2025. The...